| The covid-19 pandemic forced rapid vaccine development and market approval, shortening a process that normally takes years to just a few months. This experience raises a tantalising question: can such speed be sustained for other treatments?
To help answer the question, Merck KGaA, Darmstadt, Germany MilliporeSigma sponsored a report by Economist Impact exploring how stakeholders were able to move so quickly during a global crisis. The main takeaways: policy choices that sustain global bio-manufacturing networks, regulatory streamlining, supply chain resilience, technical support, data science to anticipate and manage supply chain risks, and the many changes in process applied during the pandemic that could aid the development of future medicines, especially with the help of advanced manufacturing.
So important that governments and Geneva negotiators implement R&D and regulatory policies that facilitate public-private collaboration, technology uptake, and bio-infrastructure development. Learn more now!
Thanks to Jennifer Brant, Oliver A. Prince, Ph.D., Anissa Boumlic-Courtade for the original research; and to Brendan O’Sullivan, Kevin Lardner, Joseph Letterman, Godfrey Firth and Jim Neville for contributing to the analysis. #vaccines #biologics #manufacturing #localization #publicprivatepartnership #techtransfer #investment |
Biopharma’s evolution: learnings from the pandemic for a revived regulatory landscape
by Carole Inglevert |
-
Carole Ingleverthttps://emergingbiotalk.com/author/carole-inglevert-2/
-
Carole Ingleverthttps://emergingbiotalk.com/author/carole-inglevert-2/
-
Carole Ingleverthttps://emergingbiotalk.com/author/carole-inglevert-2/
-
Carole Ingleverthttps://emergingbiotalk.com/author/carole-inglevert-2/
Related Posts
mRNA · News
Vaccine Maker’s Toolkit: Strategies For Manufacturing And Supply Management
This collection of insights, produced through a partnership between
Merck KGaA, Darmstadt, Germany
,[geot_filter region="north-america" country=""...
by Carole Inglevert
mRNA · News
On demand Webinar mRNA – POWERING LIFE CHANGING THERAPIES
In this webinar, join industry experts to learn about strategies to accelerate mRNA therapies and enable scalability and...
by Andrew Geall, Ph.D., Conner Feldman, Jason Sterling, Ph.D., Bastian Rouven Brückner, Ph.D. and Aditi Mehta, Ph.D.
mRNA · News
Improved endotoxin removal using ecofriendly detergents for intensified plasmid capture
Purification efficiency evaluated endotoxin and host cell protein (HCP) clearance, plasmid yield, potential interference of the detergents with...
by Carole Inglevert
mRNA · Vaccines
Post Pandemic: How a new era of supplier-vender collaboration is transforming Biopharma
Check out this article where
Merck
MilliporeSigma
's Eva Schaefer, Director of Supply Robustness,...
by Carole Inglevert
Emerging Biotech · Gene Therapy
Strengthening the CDMO-Sponsor Partnership with Improved Data Sharing and Collaboration
Collaboration between biomanufacturers and CDMOs often experiences challenges with data sharing. This presentation highlights the management of heterogenous...
by Olga Shabelnikova and Braj Nandan Thakur
mAb, ADC, recombinant · News
Are you OPEN to CLOSE your bioprocess?
In this webinar, you will: •Understand the main drivers and benefits of closed processing in biopharma, including facility...
